tbuckley/cabot-search huggingface dataset:
TCT-361 Combined use of intravascular ultrasound and optical coherence tomography during percutaneous coronary intervention may reduce target lesion revascularization after percutaneous coronary intervention
Authors: Daiji Kashiwagi, Hiromasa Otake, Toshiro Shinke, Tomofumi Takaya, Hiroto Kinutani, Takayoshi Toba, Masaru Kuroda, Hachidai Takahashi, Daisuke Terashita, Kenzo Uzu, Koji Kuroda, Yuto Shinkura, Natsuko Tahara, Yoshinori Nagasawa, Ken-ichi Hirata
Journal: Journal of the American College of Cardiology (2015)
TCT-713 Impact And Evolution Of Right Ventricular Dysfunction After MitraClip In High Risk Patients With Functional Mitral Regurgitation
Authors: Cosmo Godino, Anna Salerno, Michela Cera, Eustachio Agricola, Michele Oppizzi, Alberto Monello, Anna Giulia Pavon, Andrea Scotti, Mauro Chiarito, Valeria Magni, Alaide Chieffo, Matteo Montorfano, Alberto Cappelletti, Alberto Margonato, Antonio Colombo
Journal: Journal of the American College of Cardiology (2015)
Oncogenes and Tumor-Suppressor Genes
Authors: Teresa A. Lehman, Roger Reddel, Andrea M. A. Pfeifer, Elisa Spillare, M. Edward Kaighn, Ainsley Weston, Brenda I. Gerwin, Curtis C. Harris
Journal: Environmental Health Perspectives (1991)

The functional role of oncogenes in human lung carcinogenesis has been investigated by transfer of activated oncogenes into normal cells or an immortalized bronchial epithelial cell line, BEAS-2B. Transfection of v-Ha-ras, Ki-ras, or the combination of myc and raf into BEAS-2B cells produced tumorigenic cell lines, while transfection of raf or myc alone produced nontumorigenic cell lines. In addition to studying the pathogenic role of oncogenes, we are attempting to define negative growth-regulating genes that have tumor-suppressive effects for human lung carcinomas. Our strategy to identify tumor-suppressor genes involves loss of heterozygosity studies, monochromosome-cell fusion, and cell-cell fusion studies. Loss of heterozygosity studies have revealed consistent allelic DNA sequence deletions on chromosome 17p in squamous cell carcinomas, while large cell carcinomas and adenocarcinomas retained this locus. Mutations in p53, a tumor-suppressor gene located on chromosome 17p, have been observed. Cell-cell hybrid clones produced from fusion of nontumorigenic BEAS-2B cells with tumorigenic HuT292DM cells generally are nontumorigenic. The mechanistic role of the known tumor-suppressor genes Rb-1 and p53 in the development of human lung carcinomas is being investigated in this epithelial cell model of human bronchogenic carcinogenesis.
A Brave New World of Research Ethics
Authors: Amalia Cochran
Journal: JAMA Surgery (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Inhibition of Thrombin Generation: An Additional Biological Criterion for the Evaluation of the Anticoagulant Mechanism of Action of Generic LMWHs
Authors: Grigoris T Gerotziafas, Mouna Sassi, Vassiliki Galea, Jawed Fareed, Jeanine M. Walenga, Ismail Elalamy
Journal: Blood (2010)
Autologous Hematopoietic Stem Cell Transplantation (HCT) is a Safe and Effective Treatment for Primary Plasma Cell Leukemia: The CIBMTR Experience.
Authors: Anuj Mahindra, David Vesole, Matt E. Kalaycio, Jorge Vela-Ojeda, Smriti Shrestha, Mei-Jie Zhang, Angela Dispenzieri, Gustavo A. Milone, Sagar Lonial, Parameswaran N. Hari
Journal: Blood (2009)
Biphasic Rapamycin Effects in Lymphoma and Carcinoma Treatment
Authors: Yang Liu, Srilakshmi Pandeswara, Vinh Dao, Álvaro Padrón, Justin M. Drerup, Shunhua Lao, Aijie Liu, Vincent Hurez, Tyler J. Curiel
Journal: Cancer Research (2016)

Abstract mTOR drives tumor growth but also supports T-cell function, rendering the applications of mTOR inhibitors complex especially in T-cell malignancies. Here, we studied the effects of the mTOR inhibitor rapamycin in mouse EL4 T-cell lymphoma. Typical pharmacologic rapamycin (1–8 mg/kg) significantly reduced tumor burden via direct suppression of tumor cell proliferation and improved survival in EL4 challenge independent of antitumor immunity. Denileukin diftitox (DD)–mediated depletion of regulatory T cells significantly slowed EL4 growth in vivo in a T-cell–dependent fashion. However, typical rapamycin inhibited T-cell activation and tumor infiltration in vivo and failed to boost DD treatment effects. Low-dose (LD) rapamycin (75 μg/kg) increased potentially beneficial CD44hiCD62L+ CD8+ central memory T cells in EL4 challenge, but without clinical benefit. LD rapamycin significantly enhanced DD treatment efficacy, but DD plus LD rapamycin treatment effects were independent of antitumor immunity. Instead, rapamycin upregulated EL4 IL2 receptor in vitro and in vivo, facilitating direct DD tumor cell killing. LD rapamycin augmented DD efficacy against B16 melanoma and a human B-cell lymphoma, but not against human Jurkat T-cell lymphoma or ID8agg ovarian cancer cells. Treatment effects correlated with IL2R expression, but mechanisms in some tumors were not fully defined. Overall, our data define a distinct, biphasic mechanisms of action of mTOR inhibition at doses that are clinically exploitable, including in T-cell lymphomas. Cancer Res; 77(2); 520–31. ©2016 AACR.
Pivotal Phase 2 Study of Weekly Vincristine Sulfate Liposomes Injection (VSLI, Marqibo®) in Adults with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL) in Second Relapse or Progressing Following Two Anti-leukemia Treatment Lines.
Authors: Susan O'Brien, Gary Schiller, Lloyd E. Damon, John Lister, Farhad Ravandi, Dan Douer, Aisha Masood, Dina Ben-Yehuda, Jacob M. Rowe, Nicola Gökbuget, Walter Aulitzky, Wendy Stock, Steven Coutre, Leonard Heffner, Melissa L. Larson, Karen Seiter, Anne E Hagey, Steven R. Deitcher, Hagop M. Kantarjian
Journal: Blood (2009)
A dose escalation, single arm, phase Ib/II combination study of BEZ235 with everolimus to determine the safety, pharmacodynamics, and pharmacokinetics in subjects with advanced solid malignancies including glioblastoma multiforme.
Authors: Mohamad Adham Salkeni, Muhammad Shaalan Beg, Olugbenga Olanrele Olowokure, Hassana Fathallah, Hala Thomas, Carol A Mercer, Mahmoud Charif, Rekha T. Chaudhary, Nagla Abdel Karim, Ronald Warnick, Christopher McPherson, Ganesh Moorthy, Pankaj B Desai, Sara Kozma, George Thomas, Olivier Rixe
Journal: Journal of Clinical Oncology (2012)

TPS3116 Background: Downregulation of a number of signaling pathways, including the mammalian target of rapamycin (mTOR) pathway, has been demonstrated to be efficacious in a large range of solid tumors such as breast, colon, endometrial, glial and hepatocellular carcinoma (HCC). However, we find that rapamycins lead to suppression of a negative feedback loop from S6 Kinase 1 (S6K1) to Protein Kinase B (PKB), leading to hyperactivation of PKB. In pre-clinical studies using a mouse model of carcinogen-induced HCC, we have demonstrated that combining BEZ235 (a potent and highly selective reversible ATP site competitive inhibitor of PI3K and mTOR) with everolimus (an allosteric inhibitor of mTOR) synergizes to inhibit tumor growth. BEZ235, an orally administered agent, has demonstrated preliminary antitumor activity in a first-in-human phase I study. The current study will evaluate this combination in patients with a variety of solid malignancies that includes glioblastoma multiforme (GBM). Methods: This study is divided into a phase 1b portion designed to determine safety of increasing doses of the combination, with extensive pharmacokinetics, pharmacodynamics and pharmacogenomics analysis; and a phase 2 portion that includes both solid tumors and GBM based on predominance of the mTOR and PI3K deregulation in these tumors, to determine preliminary anti-tumor activity and the recommended dose for phase 2 studies. We will also integrate biomarker assessment for gene expression products of the mTOR downstream pathway such as eukaryotic initiation factor 4E binding protein (4EBP1) and S6 kinase (S6K). The phase 1b portion has started accruing.
TCT-294 Contrast-induced microvascular dilatation: implications for fractional flow reserve measurements
Authors: Julien Adjedj, Gabor G. Toth, Nils P. Johnson, Mariano Pellicano, Angela Ferrara, Giuseppe Di-Gioia, Vincent Floré, Emanuele Barbato, Olivier Muller, Bernard De Bruyne
Journal: Journal of the American College of Cardiology (2015)
Efficacy and safety of lipegfilgrastim compared with pegfilgrastim in patients with breast cancer who are receiving chemotherapy.
Authors: Igor Bondarenko, Oleg Gladkov, Reiner Elaesser, Anton Buchner, Peter Bias
Journal: Journal of Clinical Oncology (2012)

e19587 Background: Cancer chemotherapy frequently causes neutropenia, leading to an increased risk of infections and delays in subsequent chemotherapy treatments. Pegfilgrastim is a pegylated recombinant form of granulocyte colony stimulating factor (G-CSF) that extends the half-life and requires less frequent dosing than nonpegylated G-CSF. Lipegfilgrastim is a glycosylated and pegylated G-CSF. The objective of this study was to compare the efficacy and safety of lipegfilgrastim and pegfilgrastim in chemotherapy-naïve patients with breast cancer who are candidates to receive docetaxel/doxorubicin. Methods: In this double-blind, randomized, active-controlled, noninferiority trial, patients with high-risk stage II, III, or IV breast cancer and an absolute neutrophil count ≥1.5x10 9 cells/L were randomly assigned to lipegfilgrastim 6 mg (n=101) or pegfilgrastim 6 mg (n=101). Study medication was injected subcutaneously on day 2 of the chemotherapy cycle (4 cycles maximum). Primary efficacy endpoint was the duration of severe neutropenia (days with an absolute neutropenia count &lt;0.5x10 9 cells/L) during cycle 1. Secondary endpoints included the incidence of febrile neutropenia. Efficacy analysis population included patients who were randomized but did not have major protocol violations. Results: Overall, 37%, 46%, and 17% of patients had stage II, III, and IV breast cancer, respectively. The mean duration of severe neutropenia in cycle 1 was 0.7 days in the lipegfilgrastim group and 0.8 days in the pegfilgrastim group (poisson regression least squares mean [95% CI] -0.218 [-0.498 to 0.062]). 56% and 49%, respectively, did not experience severe neutropenia in cycle 1. Three patients experienced febrile neutropenia; all were in the pegfilgrastim group during cycle 1. 28% of patients in the lipegfilgrastim group and 26% in the pegfilgrastim group had adverse events that the investigator considered to be related to study medication. Three and 7 patients, respectively had serious adverse events. Conclusions: The results of this study confirm that the efficacy of lipegfilgrastim is comparable with pegfilgrastim. No unexpected safety events were observed.
Microneedle‐assisted incubation during aminolaevulinic acid photodynamic therapy of actinic keratoses: a randomized controlled evaluator‐blind trial
Authors: H. Lev‐Tov, L. Larsen, R. Zackria, H. Chahal, D.B. Eisen, R.K. Sivamani
Journal: British Journal of Dermatology (2016)

Photodynamic therapy (PDT) is a common method of treating actinic keratoses (AKs) that compares favorably to other treatment methods.(1,2) However, treatment is limited by prolonged incubation times required for the medication to penetrate the stratum corneum.(3) Microneedles (MNs) are micrometer scale needles that are capable of puncturing the stratum corneum with minimal pain.(4,5) They have been utilized for various applications, including enhanced drug delivery.6 Few studies have evaluated MNs in conjunction with PDT for AKs.(7) We sought to assess the utility of short solid MN arrays that penetrate to the epidermis in shortening the incubation time for aminolevulinic acid (ALA) in PDT for AKs. This article is protected by copyright. All rights reserved.
Progress Toward Global Eradication of Dracunculiasis — January 2017–June 2018
Authors: Donald R. Hopkins, Ernesto Ruiz-Tiben, Adam J. Weiss, Sharon L. Roy, James Zingeser, Sarah Anne J. Guagliardo
Journal: MMWR Morbidity and Mortality Weekly Report (2018)

With only 30 dracunculiasis cases in humans reported in 2017, the goal of eradicating Guinea worm disease appears to be on the horizon. However, infections in dogs and insecurity in Mali and South Sudan remain challenges to eradication efforts.
Dexamethasone and Individualized Asparaginase Dosing Are Each Associated with Superior Event-Free Survival in Childhood Acute Lymphoblastic Leukemia: Results From DFCI-ALL Consortium Protocol 00-01.
Authors: Lynda M. Vrooman, Donna S. Neuberg, Kristen E. Stevenson, Jeffrey G. Supko, Stephen E. Sallan, Lewis B. Silverman
Journal: Blood (2009)
VEGFR-1 (Flt-1) Tyrosine Kinase Signaling Enhances Hematopoiesis, Proliferation/Differentiation and Immunity of Monocyte/Macrophage from Bone Marrow Hematopoietic Stem Cells, and Promotes Rheumatoid Arthritis.
Authors: Masato Murakami, Shinobu Iwai, Sachie Hirasuka, Yoichiro Iwakura, Yoshiro Maru, Masabumi Shibuya
Journal: Blood (2004)
TSP1–CD47 signaling is upregulated in clinical pulmonary hypertension and contributes to pulmonary arterial vasculopathy and dysfunction
Authors: Natasha M. Rogers, Maryam Sharifi-Sanjani, Mingyi Yao, Kedar Ghimire, Raquel Bienes-Martinez, Stephanie M. Mutchler, Heather E. Knupp, Jeffrey Baust, Enrico M. Novelli, Mark Ross, Claudette St. Croix, Johannes C. Kutten, Caitlin A. Czajka, John C. Sembrat, Mauricio Rojas, David Labrousse-Arias, Timothy N. Bachman, Rebecca R. Vanderpool, Brian S. Zuckerbraun, Hunter C. Champion, Ana L. Mora, Adam C. Straub, Richard A. Bilonick, Maria J. Calzada, Jeffrey S. Isenberg
Journal: Cardiovascular Research (2016)

Thrombospondin-1 (TSP1) is a ligand for CD47 and TSP1−/− mice are protected from pulmonary hypertension (PH). We hypothesized the TSP1–CD47 axis is upregulated in human PH and promotes pulmonary arterial vasculopathy. We analyzed the molecular signature and functional response of lung tissue and distal pulmonary arteries (PAs) from individuals with (n = 23) and without (n = 16) PH. Compared with controls, lungs and distal PAs from PH patients showed induction of TSP1–CD47 and endothelin-1/endothelin A receptor (ET-1/ETA) protein and mRNA. In control PAs, treatment with exogenous TSP1 inhibited vasodilation and potentiated vasoconstriction to ET-1. Treatment of diseased PAs from PH patients with a CD47 blocking antibody improved sensitivity to vasodilators. Hypoxic wild type (WT) mice developed PH and displayed upregulation of pulmonary TSP1, CD47, and ET-1/ETA concurrent with down regulation of the transcription factor cell homolog of the v-myc oncogene (cMyc). In contrast, PH was attenuated in hypoxic CD47−/− mice while pulmonary TSP1 and ET-1/ETA were unchanged and cMyc was overexpressed. In CD47−/− pulmonary endothelial cells cMyc was increased and ET-1 decreased. In CD47+/+ cells, forced induction of cMyc suppressed ET-1 transcript, whereas suppression of cMyc increased ET-1 signaling. Furthermore, disrupting TSP1–CD47 signaling in pulmonary smooth muscle cells abrogated ET-1-stimulated hypertrophy. Finally, a CD47 antibody given 2 weeks after monocrotaline challenge in rats upregulated pulmonary cMyc and improved aberrations in PH-associated cardiopulmonary parameters. In pre-clinical models of PH CD47 targets cMyc to increase ET-1 signaling. In clinical PH TSP1–CD47 is upregulated, and in both, contributes to pulmonary arterial vasculopathy and dysfunction.
Polymorphisms of Methylenetetrahydrofolate Reductase Gene and Risk of Ischemic Stroke in a Spanish Population.
Authors: Raquel De Ona, Pilar Llamas, Jaime Fernandez De Velasco, Ana Belen Santos, Elena Meseguer, Arancha Garcia-Raso, Raquel Mata, Jose Francisco Tomas
Journal: Blood (2004)
Comparison Of Mutation Patterns Between Diagnosis and Relapse In 556 Adult Patients With AML Shows High Variability Of Stability
Authors: Susanne Schnittger, Niroshan Nadarajah, Tamara Alpermann, Christiane Eder, Alexander Kohlmann, Sabrina Kuznia, Sandra Weissmann, Annette Fasan, Simone Weber, Andreia Albuquerque, Sabine Jeromin, Manja Meggendorfer, Frank Dicker, Wolfgang Kern, Claudia Haferlach, Torsten Haferlach, MD
Journal: Blood (2013)
A Variant of Congenital Neutropenia Is Caused by a 3′-UTR Mutation in the Gene Encoding the Endosomal Adaptor Protein p14 (MAPBPIP).
Authors: Georg Bohn, Anna Allroth, Jens Thiel, Alejandro A. Schäffer, Gudrun Brandes, Erik Glocker, David Teis, Nicole Taub, Cornelia Zeidler, Robert Geffers, Jan Buer, Lukas A. Huber, Karl Welte, Bodo Grimbacher, Christoph Klein
Journal: Blood (2005)
Systematic Comparison of the EF-1 Alpha Short (EFS) and Viral Promoters for Gene Modification of Human Primary Cells for Clinical Applications
Authors: Roy L. Kao, Eric H. Gschweng, Avigael Rebecca Lerman, Sarah M. Larson, Andy Tu, Tulika Tyagi, Shantha Senadheera, Roger P. Hollis, Satiro N. De Oliveira
Journal: Blood (2014)
Connecting (T)issues: How Research in Fascia Biology Can Impact Integrative Oncology
Authors: Helene M. Langevin, Patricia Keely, Jun Mao, Lisa M. Hodge, Robert Schleip, Gary Deng, Boris Hinz, Melody A. Swartz, Beverley A. de Valois, Suzanna Zick, Thomas Findley
Journal: Cancer Research (2016)

Abstract Complementary and integrative treatments, such as massage, acupuncture, and yoga, are used by increasing numbers of cancer patients to manage symptoms and improve their quality of life. In addition, such treatments may have other important and currently overlooked benefits by reducing tissue stiffness and improving mobility. Recent advances in cancer biology are underscoring the importance of connective tissue in the local tumor environment. Inflammation and fibrosis are well-recognized contributors to cancer, and connective tissue stiffness is emerging as a driving factor in tumor growth. Physical-based therapies have been shown to reduce connective tissue inflammation and fibrosis and thus may have direct beneficial effects on cancer spreading and metastasis. Meanwhile, there is currently little knowledge on potential risks of applying mechanical forces in the vicinity of tumors. Thus, both basic and clinical research are needed to understand the full impact of integrative oncology on cancer biology as well as whole person health. Cancer Res; 76(21); 6159–62. ©2016 AACR.
Blood baseline neutrophil count to predict bevacizumab efficacy in glioblastoma.
Authors: Aurelie Bertaut, Romain Boidot, Rachid Madkouri, Coureche guillaume Kaderbhai, Julie Vincent, Bruno Chauffert, Francois Ghiringhelli
Journal: Journal of Clinical Oncology (2016)

2024 Background: Bevacizumab is frequently used at recurrence of glioblastoma. However, no biomarker could predict its efficacy. Methods: Exploratory cohort consisted in all patients treated with Stupp regimen for a glioblastoma in Dijon cancer center (N = 265). A validation cohort was TEMAVIR trial which compared 120 patients suffering from glioblastoma treated with Stupp regimen versus bevacizumab plus irinotecan followed by Stupp regimen plus bevacizumab. CSF3 expression was determined in a cohort of 202 patients from the cancer genome atlas. Prognosis role of CSF3expression was next determined in an independent cohort of 23 patients treated with bevacizumab for a recurrent glioblastoma. Results: In the exploratory cohort, bevacizumab increased median overall survival (OS) 18.7 vs 11.3 months, p = 0.0014. Upon multivariate analysis, the age, type of initial surgery, neutrophil count, Karnofsky status > 70%, bevacizumab administration were an independent prognosis factors of survival. We detected an interaction between bevacizumab use and neutrophil count at baseline. Cut off value of neutrophil count was set at 6000/mm3. Only patients with a high level of neutrophil benefited in term of overall survival from the bevacizumab administration (17.3 months (CI95% 14.6-20.4) for patients that received bevacizumab versus vs 8.8 months CI95% 6.4-10.3) for others (p < 0.0001)). Overall survival was not significantly improved for remaining patients treated with bevacizumab with low neutrophil count (21.6 months (CI95% 18.0-23.3) for patients that received bevacizumab versus 15.9 months (CI95%12.0-19.9) for the others (p = 0.7313)).Similar results were obtained in the TEMAVIR trial. Transcriptomic data underlined that expression of CSF3, the gene encoding G-CSF, was correlated with VEGF-A expression. In another independent cohort, we also observed this association between high CSF3expression in tumor and a better survival in patients treated with bevacizumab at recurrence. Conclusions: Only patients with a high level of neutrophil before initiation of bevacizumab treatment benefited from this therapy. Neutrophil count at baseline is a predictive biomarker of efficacy of bevacizumab for glioblastoma bearing patients
Spinning a Yarn—Sleeping Beauty and Anthrax
Authors: Jason Giacomel, Iris Zalaudek
Journal: JAMA Dermatology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Novel CXCR4-Targeted Therapy to Inhibit Multiple Myeloma Bone Dissemination
Authors: Aldo M Roccaro, Antonio Sacco, Michele Moschetta, Yuji Mishima, Patricia Maiso, Daisy Huynh, Marco Chiarini, Pina M. Cardarelli, Lewis Cohen, Michelle Kuhne, Irene M. Ghobrial
Journal: Blood (2014)
TCT-88 Transcatheter Perivascular Chemical Neurolysis to Produce Renal Denervation: Targeted, Local Delivery of Alcohol as a Viable Alternative to Radiofrequency Approaches
Authors: Tim Fischell, Felix Vega, Darrin J. Kent, Stefan C. Bertog, Narayan Raju, Elena Ladich, Kazuyuki Yahagi, Renu Virmani, Vartan E. Ghazarossian
Journal: Journal of the American College of Cardiology (2015)
Role of Microenvironment-Associated Chemokines and Cytokines for Binet Stage A CLL Patients Included in a Prospective Trial (CLL1 trial) of the German CLL Study Group (GCLLSG): sIl2Ralpha Is An Independent Predictor of Progression-Free Survival (PFS),
Authors: Till M Seiler, Roland Aydin, Tobias Herold, Raymonde Busch, Markus Schwarz, Stefan Holdenrieder, Barbara Eichhorst, Hartmut Dohner, Stephan Stilgenbauer, Michael Hallek, Martin H. Dreyling, Manuela A. Bergmann
Journal: Blood (2011)